Financial Statements · From SEC 10-K & 10-Q XBRL Filings
Revolution Medicines Inc. Revenue & Financial Statements
Revolution Medicines Inc. reported revenue of $0 for the fiscal year ended December 31, 2025, with net income of $(1.1B) and diluted EPS of $-5.95.
- Company
- Revolution Medicines Inc. RVMD · NASDAQ
- Latest fiscal year
- FY ended Dec 31, 2025
- Statements
- Income · Balance Sheet · Cash Flow — 5 fiscal years, 8 quarters
Income Statement
Annual, as reported in 10-K filings. Values in USD.
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | 29.4M | 35.4M | 11.6M | 0 | 0 |
| Cost of revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | (188.0M) | (258.3M) | (487.2M) | (689.5M) | (1.2B) |
| Pretax income | (187.1M) | (249.1M) | (439.9M) | (600.8M) | 0 |
| Net income | (187.1M) | (248.7M) | (436.4M) | (600.1M) | (1.1B) |
| Diluted EPS | — | -3.08 | -3.86 | -3.58 | -5.95 |
| EBITDA | (184.9M) | (254.3M) | (482.1M) | (683.3M) | (1.2B) |
Quarterly
| USD | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | (140.9M) | (156.6M) | (175.7M) | (216.3M) | (240.8M) | (264.7M) | (315.3M) | (361.6M) |
| Pretax income | (116.0M) | (133.2M) | (156.3M) | (195.3M) | (213.4M) | (247.8M) | (305.2M) | (364.9M) |
| Net income | (116.0M) | (133.2M) | (156.3M) | (194.6M) | (213.4M) | (247.8M) | (305.2M) | (364.9M) |
| Diluted EPS | -0.70 | -0.81 | -0.94 | -1.13 | -1.13 | -1.31 | -1.61 | -1.89 |
| EBITDA | (139.3M) | (155.0M) | (174.1M) | (214.9M) | (239.2M) | (263.0M) | (313.3M) | (359.5M) |
Balance Sheet
Fiscal year-end snapshots. Values in USD.
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Total assets | 738.0M | 811.9M | 2.1B | 2.6B | 2.4B |
| Current assets | 589.8M | 660.2M | 1.9B | 2.3B | 2.1B |
| Cash & equivalents | 108.5M | 161.4M | 696.1M | 543.1M | 383.7M |
| Total liabilities | 135.4M | 126.7M | 235.5M | 293.1M | 723.2M |
| Current liabilities | 60.4M | 62.0M | 143.9M | 163.9M | 290.4M |
| Long-term debt | — | — | — | — | — |
| Total debt | — | — | — | — | — |
| Stockholders’ equity | 602.6M | 685.2M | 1.8B | 2.3B | 1.6B |
| Net debt | — | — | — | — | — |
Cash Flow Statement
Annual, as reported in 10-K filings. Values in USD.
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Operating cash flow | (147.2M) | (224.4M) | (350.6M) | (557.4M) | (897.7M) |
| Investing cash flow | (142.1M) | (24.1M) | (342.6M) | (554.4M) | 118.1M |
| Financing cash flow | 294.2M | 301.4M | 1.2B | 959.4M | 621.5M |
| Capital expenditure | 6.5M | 10.8M | 7.7M | 10.3M | 16.0M |
| Free cash flow | (153.7M) | (235.2M) | (358.3M) | (567.7M) | (913.7M) |
| Dividends paid | — | — | — | — | — |
| Stock-based compensation | 20.7M | 31.2M | 61.8M | 79.2M | 118.4M |
Figures are parsed from SEC XBRL company facts and may be derived where issuers report year-to-date values (quarterly figures differenced; Q4 computed as FY minus Q3). Fiscal periods follow each company's fiscal calendar, not calendar years. Historical fact, not investment advice — verify with official SEC filings.
Every RVMD filing, connected
Financials beside price, insider trades, and 8-K events — with alerts the moment something new is filed.